Serial quantification of lymphoid and myeloid mixed chimerism using multiplex PCR amplification of short tandem repeat-markers predicts graft rejection and relapse, respectively, after allogeneic transplantation of CD34+ selected cells from peripheral blood

Leukemia

Volumn 17, Issue 3, 2003, Pages 613-620

  Fernandez Aviles F ^a   Urbano Ispizua, A ^a   Aymerich, M ^a   Colomer, D ^a   Rovira, M ^a   Martinez C ^a   Nadal, E ^a   Talarn, C ^a   Carreras, E ^a   Montserrat, E ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

CD34+ selection; Chimerism; PCR STR; T cell depletion

Indexed keywords

CD34 ANTIGEN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYCLOSPORIN A; GRANULOCYTE COLONY STIMULATING FACTOR; METHOTREXATE;

ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ALLOTRANSPLANTATION; ARTICLE; CANCER RECURRENCE; CELL SELECTION; CONTROLLED STUDY; FEMALE; GENE AMPLIFICATION; GRAFT FAILURE; GRAFT REJECTION; HEMATOPOIESIS; HISTOCOMPATIBILITY; HOST CELL; HUMAN; HUMAN CELL; LYMPHOCYTE DEPLETION; MAJOR CLINICAL STUDY; MALE; NEUTROPHIL; POLYMERASE CHAIN REACTION; PREDICTION; PRIORITY JOURNAL; RECIPIENT; STEM CELL TRANSPLANTATION; T LYMPHOCYTE SUBPOPULATION; TANDEM REPEAT;

EID: 0345270451     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2402854     Document Type: Article

References (50)

1. Urbano-Ispizua A, Rozman C, Pimentel P, Solano C, de la Rubia J, Brunet S et al. The number of donor CD3(+) cells is the most important factor for graft failure after allogeneic transplantation of CD34(+) selected cells from peripheral blood from HLA-identical siblings. Blood 2001; 97: 383-387.
2. Socié G, Cayuela JM, Raynal B, Esperou H, Fund X, Raffoux C et al. Influence of CD34 cell selection on the incidence of mixed chimearism and minimal residual disease after allogeneic unrelated donor transplantation. Leukemia 1998; 12: 1440-1446.
3. Briones J, Urbano-Ispizua A, Lawler M, Rozman C, Gardiner N, Martínez C et al. High frequency of donor chimerism after allogeneic transplantation of CD34+- selected peripheral blood cells. Exp Hematol 1998; 26: 415-420.
4. Mackinnon S, Barnett L, Heller G, O'Reilly RJ. Minimal residual disease is more common in patients who have mixed T-cell chimerism after bone marrow transplantation for chronic myelogenous leukemia. Blood 1994; 83: 3409-3416.
5. Roux E, Helg C, Dumont-Gerard F, Chapuis B, Jeannet M, Roosnek E. Analysis of T-cell repopulation after allogeneic bone marrow transplantation: significant differences between recipients of T-cell depleted and unmanipulated grafts. Blood 1996; 87: 3984-3992.
6. Mackinnon S, Barnett L, Heller G. Polymerase chain reaction is highly predictive of relapse in patients following T cell-depleted allogeneic bone marrow transplantation for chronic myeloid leukemia. Bone Marrow Transplant 1996; 17: 643-647.
7. Roux E, Abdi K, Speiser D, Helg C, Chapuis B, Jeannet M et al. Characterisation of mixed chimerism in patients with chronic myeloid leukemia transplanted with T-cell-depleted bone marrow: involvement of different hematologic lineages before and after relapse. Blood 1993; 81: 243-248.
8. Mackinnon S, Barnett L, Bourhis JH, Black P, Heller G, O'Reily RJ. Myeloid and lymphoid chimerism after T-cell-depleted bone marrow transplantation: evaluation of conditioning regimens using the polymerase chain reaction to amplify human minisatellite regions of genomic DNA. Blood 1992; 80: 3235-3241.
9. Gonzalez M, Lopez-Perez R, Garcia-Sanz R, Perez-Simon JA, San Miguel JF. Debate round-table: comments concerning chimerism studies. Leukemia 2001; 15: 1986-1988.
10. Klingebiel T, Niethammer D, Dietz K, Bader P. Progress in chimerism analysis in childhood malignancies - the dilemma of biostatistical considerations and ethical implications. Leukemia 2001; 15: 1989-1991.
11. Lawler M. Prospective chimerism analysis, the time is now but can we respond? Leukemia 2001; 15: 1992-1994.
12. Biondi A, Balduzzi A. Questions on chimerism analysis after stem cell transplantation. Leukemia 2001; 15: 1995.
13. Gyger M, Baron C, Forest L, Lussier P, Lagacé F, Bissonnette I et al. Quantitative assessment of hematopoietic chimerism after allogeneic bone marrow transplantation has predictive value for the occurrence of irreversible graft failure and graft-vs.-host disease. Exp Hematol 1998; 26: 426-434.
14. BCR-ABL detection precede cytogenetic relapse. Blood 2000; 95: 2659-2665.
15. Bader P, Stoll K, Huber S, Geiselhart A, Handgretinger R, Niemeyer C et al. Characterization of lineage-specific chimerism in patients with acute leukemia and myelodysplastic syndrome after allogeneic stem cell transplantation before and after relapse. Br J Haematol 2000; 108: 761-768.
16. Roy DC, Tantravahi R, Murray C, Dear K, Gorgone B, Anderson KC et al. Natural history of mixed chimerism after bone marrow transplantation with CD6-depleted allogeneic marrow: a stable equilibrium. Blood 1990; 75: 296-304.
17. Miflin G, Stainer CJ, Carter GI, Byrne JL, Haynes AP, Russell NH. Comparative serial quantitative measurements of chimaerism following unmanipulated allogeneic transplantation of peripheral blood stem cells and bone marrow. Br J Haematol 1999; 107: 429-440.
18. Wäsch R, Bertz H, Kunzmann R, Finke J. Incidence of mixed chimaerism and clinical outcome in 101 patients after myeloablative conditioning regimens and allogeneic stem cell transplantation. Br J Haematol 2000; 109: 743-750.
19. McSweeney PA, Storb R. Mixed chimerism: preclinical studies and clinical applications. Biol Blood Marrow Transplant 1999; 5: 192-203.
20. Roman J, Martín C, Torres A, García A, Andrés P, García MJ et al. Importance of mixed chimerism to predict relapse in persistently bcr-abl long survivors after bone marrow transplantation for chronic myelogenous leukemia. Leukemia Lymphoma 1998; 28: 541-550.
21. + lymphocytes is associated with a higher incidence of relapse. Bone Marrow Transplant 1999; 23: 475-482.
22. Bader P, Hölle W, Klingebiel T, Handgretinger R, Benda N, Schlegel P et al. Mixed hematopoietic chimerism after allogeneic bone marrow transplantation: the impact of quantitative PCR analysis for prediction of relapse and graft rejection in children. Bone Marrow Transplant 1997; 19: 697-702.
23. Bader P, Beck J, Frey A, Schlegel PG, Hebarth H, Handgretinger R et al. Serial and quantitative analysis of mixed hematopoietic chimerism by PCR in patients with acute leukemias allows the prediction of relapse after allogeneic BMT. Bone Marrow Transplant 1998; 21: 487-495.
24. van Leeuwen JE, van Tol MJ, Joosten AM, Wijnen JT, Verweij PJ, Khan PM et al. Persistence of host-type hematopoiesis after allogeneic bone marrow transplantation for leukemia is significantly related to the recipient's age and/or the conditioning regimen, but it is not associated with an increased risk of relapse. Blood 1994; 83: 3059-3067.
25. Suttorp M, Schmitz N, Dreger P, Schaub J, Loffler H. Monitoring of chimerism after allogeneic bone marrow transplantation with unmanipulated marrow by the use of DNA polymorphisms. Leukemia 1993; 7: 679-687.
26. Maury S, Jouault H, Kuentz M, Vernant JP, Tulliez M, Cordonnier C et al. Chimerism analysis by lineage-specific fluorescent polymerase chain reaction in secondary graft failure after allogeneic stem cell transplantation. Transplantation 2001; 71: 374-380.
27. Wiesneth M, Schreiner T, Bunjes D, Bischof C, Erne E, Maccari B et al. Comparison of T-cell-depleted BMT and PBPCT with respect to chimerism, graft rejection, and leukemic relapse. J Hematother 1999; 8: 269-274.
28. Lion T, Daxberger H, Dubovsky J, Filipcik P, Fritsch G, Printz D et al. Analysis of chimerism within specific leukocyte subsets for detection of residual or recurrent leukemia in pediatric patients after allogeneic stem cell transplantation. Leukemia 2001; 15: 307-310.
29. + selected cells from peripheral blood. Blood 1997; 89: 3967-3973.
30. + cells? Blood 2001; 98: 2352-2357.
31. Boyum A. Separation of leukocytes from blood and bone marrow. Scand J Clin Invest 1968; 21: 51-55.
32. Thiede C, Bornhäuser M, Oelschlägel U, Brendel C, Leo R, Daxberger H et al. Sequential monitoring of chimerism and detection of minimal residual desease after allogeneic blood stem cell transplantation (BSCT) using multiplex PCR amplification of short tandem repeat-markers. Leukemia 2001; 15: 293-302.
33. Thiede C, Lion T. Quantitative analysis of chimerism after allogeneic stem cell transplantation using multiplex PCR amplification of short tandem repeat markers and fluorescence detection. Leukemia 2001; 13: 303-306.
34. Gardiner N, Lawler M, O'Riordan J, DeArce M, Humphries P, MacCann SR. Persistent donor chimaerism is consistent with disease-free survival following BMT for chronic myeloid leukaemia. Bone Marrow Transplant 1997; 20: 235-241.
35. + HLA-DR-bone marrow cells after allogeneic peripheral blood transplantation with a long follow-up. Bone Marrow Transplant 1998; 21: 189-194.
36. Childs R, Clave E, Contentin N, Jayasekera D, Hensel N, Leitman S et al. Engraftment kinetics after non-myeloablative allogeneic peripheral blood stem cell transplantation: full donor T-cell chimerism precedes alloimmune responses. Blood 1999; 94: 3234-3241.
37. De Weger RA, Tilanus MGJ, Scheidel KC, Van den Tweel JG, Verdonck LF. Monitoring of residual disease and guided donor leucocyte infusion after allogeneic bone marrow transplantation by chimearism analysis with short tandem repeats. Br J Haematol 2000; 110: 647-653.
38. Bordignon C, Keever CA, Small TN, Flomenberg N, Dupont B, O'Reily RJ et al. Graft failure after T-cell-depleted human leukocyte antigen identical marrow transplants for leukemia: II. In vitro analyses of host effector mechanisms. Blood 1989; 74: 2237-2243.
39. Olavarria E, Kanfer E, Szydlo R, Kaeda J, Rezvani K, Cwynarski K et al. Early detection of BCR-ABL transcripts by quantitative reverse transcriptase-polymerase chain reaction predicts outcome after allogeneic stem cell transplantation for chronic myeloid leukemia. Blood 2001; 97: 1560-1565.
40. van Leeuwen JE, van Tol MJ, Joosten AM, Wijnen JT, Khan PM, Vossen JM. Mixed T-lymphoid chimerism after allogeneic bone marrow transplantation for hematologic malignancies of children is not correlated with relapse. Blood 1993; 82: 1921-1928.
41. Schaap N, Schattenberg A, Mensink E, Preijers F, Hillegers M, Knops R et al. Long-term follow-up of persisting mixed chimerism after partially T cell-depleted allogeneic stem cell transplantation. Leukemia 2002; 16: 13-21.
42. Molloy K, Goulden N, Lawler M, Cornish J, Oakhill A, Pamphilon D et al. Patterns of hematopoietic chimerism following bone marrow transplantation for childhood acute lymphoblastic leukemia from volunteer unrelated donors. Blood 1996; 87: 3027-3031.
43. Mattsson J, Uzunel M, Tammik L, Aschan J, Ringdén O. Leukemia lineage-specific chimerism analysis is a sensitive predictor of relapse in patients with acute myeloid leukemia and myelodysplastic syndrome after allogeneic stem cell transplantation. Leukemia 2001; 15: 1976-1985.
44. Billiau AD, Fevery S, Rutgeerts O, Landuyt W, Waer M. Crucial role of timing of donor lymphocyte infusion in generating dissociated graft-versus-host and graft-versus-leukemia responses in mice receiving allogeneic bone marrow transplants. Blood 2002; 100: 1894-1902.
45. Mapara MY, Kim YM, Wang SP, Bronson R, Sachs DH, Sykes M. Donor lymphocyte infusions mediate superior graft-versus-leukemia effects in mixed compared to fully allogeneic chimeras: a critical role for host antigen-presenti ng cells. Blood 2002; 100: 1903-1909.
46. Mattsson J, Uzunel M, Remberger M, Ringden O. T cell mixed chimerism is significantly correlated to a decreased risk of acute graft-versus-host disease after allogeneic stem cell transplantation. Transplantation 2001; 71: 433-439.
47. Thomson AW, Lu L, Murase N, Demetris AJ, Rao AS, Starzl TE. Microchimerism, dendritic cell progenitors and transplantation tolerance. Stem Cells 1995; 13: 622-639.
48. Shimoni A, Nagler A. Non-myeloablative stem cell transplantation (NST): chimerism testing as guidance for immune-therapeutic manipulations. Leukemia 2001; 15: 1967-1975.
49. Shlomchik WD, Couzens MS, Tang CB, McNiff J, Robert ME, Liu J et al. Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science 1999; 285: 412-415.
50. Waller EK, Rosenthal H, Jones TW, Peel J, Lonial S, Langston et al. Larger numbers of CD4bright dendritic cells in donor bone marrow are associated with increased relapse after allogeneic bone marrow transplantation. Blood 2001; 97: 2948-2956.